Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

Phase 1 Completed 22 enrolled Arcutis Biotherapeutics, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile and assess the safety and tolerability of ARQ-154 foam 0.3%.

Timeline

Start: 2025-12-15
Primary completion: 2026-04-30
Completion: 2026-04-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ARQ-154	Unknown	0.3 %	—

Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

Summary

Timeline

Drugs

Indications